Carmat's implantable artificial heart clinical trial begins
advertisement
Ubicación actual:
>
> This Story


Conexión o Registro to rate this News Story
Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

Cardiology Homepage

New 3D bioprinting method can create organs from collagen Major structural protein in the human body

Key success criteria for the creation of an outpatient heart failure clinic Deb Thompson, senior consulting manager for Cardiology at Philips discusses what is required for the efficient management of a multi-disciplinary heart care team

New AI solution identifies high-risk patients from chest X-rays MGH tool may help detect heart disease, lung cancer

Cardiology occupies a unique space in medical informatics Looking at enterprise imaging and informatics through the lens of cardiology at SIIM

MiE showcases cardiac PET scanner, Ancoris, at SNMMI Provides simultaneous 3D cardiac PET perfusion and CFR

AI tool for Alexa and smart devices detects cardiac arrest in sleeping patients Monitors patients for agonal breathing

Mount Sinai surgeons first in NY to perform minimally-invasive heart bypass surgery Only for highly-skilled surgeons for now

New dye helps control 'lighting' for sharper images of heart May help identify early signs of heart disease

Evaluating the cost-effectiveness of AEDs in the U.S. Insights from Dr. Lars W. Andersen on research he conducted and what it should mean for the future of public defibrillators

The 2019 Heart Rhythm Society scientific sessions: advanced technology in electrophysiology Four key takeaways

Carmat's implantable artificial heart clinical trial begins

por Thomas Dworetzky , Contributing Reporter
French artificial heart developer Carmat has launched a European trial of its leading-edge device with the first implantation of its device in 20-patient clinical trial.

It hopes the results from the trial will let it gain European Union CE Mark approval for its bio-prosthetic heart.

Story Continues Below Advertisement

THE (LEADER) IN MEDICAL IMAGING TECHNOLOGY SINCE 1982. SALES-SERVICE-REPAIR

Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.



The device aims “to provide a therapeutic alternative for people suffering from end-stage bi-ventricular heart failure,” Carmat said in a statement.

An earlier feasibility trial of four implants began in 2013. The procedure was performed on December 18 by a Georges Pompidou European Hospital team in Paris – a world first, according to a statement at the time.

In that initial feasibility trial three patients survived implant – for nine months, seven months and 2.5 months, respectively.

The last patient survived only 20 days post-op. Physicians determined in this last case that the underlying disease was so severe that it caused the death. That patient had already been on life support at the time of surgery, according to Seeking Alpha.

“Carmat aims to eventually provide a response to a major public health issue associated with heart disease, the world’s leading cause of death – chronic and acute heart failure,” according to a recent company statement. “By pursuing the development of its total artificial heart, Carmat intends to overcome the well-known shortfall in heart transplants for the tens of thousands of people suffering from irreversible end-stage heart failure, the most seriously affected of the 20 million patients with this progressive disease in Europe and the U.S.”

Data from the latest trial will be published, stated the firm, but only “in accordance with good clinical practice.” adding, “the company it is not planning to publish specific information concerning the implantations of each patient involved in the study or their condition.”

The announcement comes at a time when SynCardia Systems, the sole seller of artificial hearts, has filled for chapter 11 bankruptcy.

“SynCardia’s machine works quite well,” noted Carmat’s chief executive, Marcello Conviti, according to Seeking Alpha. “But it’s a very old machine with a big air compressor … I’m not surprised that they’re heading out of the market.”

SynCardia's machines had been implanted in thousands of patients worldwide, with some using it for over three years.

The fully implantable heart's design is the result of combining the medical expertise ofProfessor Alain Carpentier, known for inventing Carpentier-Edwards heart valves, and the technological expertise of aerospace firm the Airbus Group.

The device resembles a natural heart in size, and through its choice of structural materials and physiological functions, according to Carmat.

Carmat's founders and investors include: Airbus Group (Matra Défense), Carpentier, the Centre Chirurgical Marie Lannelongue, Truffle Capital, a leading European venture capital firm, ALIAD, Air Liquide’s venture capital investor, CorNovum, an investment holding company held 50-50 by Bpifrance and the French State, the family offices of Pierre Bastid and of Dr. Antonino Ligresti.

Carmat shares jumped as high as 10 percent in early trading in Paris on the news of its trail-launching transplant, according to Reuters.

Cardiology Homepage


You Must Be Logged In To Post A Comment